Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States

Author:

Mozaffari Essy1,Chandak Aastha2ORCID,Zhang Zhiji2,Liang Shuting1,Gayle Julie3,Thrun Mark1,Gottlieb Robert L4567,Kuritzkes Daniel R8,Sax Paul E8,Wohl David A9,Casciano Roman2ORCID,Hodgkins Paul1,Haubrich Richard1

Affiliation:

1. Gilead Sciences, Foster City, California, USA

2. Certara, New York, New York, USA

3. Premier Inc., Charlotte, North Carolina, USA

4. Baylor University Medical Center, Dallas, Texas, USA

5. Baylor Scott and White Heart and Vascular Hospital, , Dallas, Texas, USA

6. Baylor Scott and White The Heart Hospital, Plano, Texas, USA

7. Baylor Scott and White Research Institute, Dallas, Texas, USA

8. Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

9. University of North Carolina, Chapel Hill, North Carolina, USA

Abstract

Abstract Background The objective of this study was to characterize hospitalized coronavirus disease 2019 (COVID-19) patients and describe their real-world treatment patterns and outcomes over time. Methods Adult patients hospitalized on May 1, 2020–December 31, 2020 with a discharge diagnosis of COVID-19 were identified from the Premier Healthcare Database. Patient and hospital characteristics, treatments, baseline severity based on oxygen support, length of stay (LOS), intensive care unit (ICU) utilization, and mortality were examined. Results The study included 295657 patients (847 hospitals), with median age of 66 (interquartile range, 54–77) years. Among each set of demographic comparators, the majority were male, white, and over 65. Approximately 85% had no supplemental oxygen charges (NSOc) or low-flow oxygen (LFO) at baseline, whereas 75% received no more than NSOc or LFO as maximal oxygen support at any time during hospitalization. Remdesivir (RDV) and corticosteroid treatment utilization increased over time. By December, 50% were receiving RDV and 80% were receiving corticosteroids. A higher proportion initiated COVID-19 treatments within 2 days of hospitalization in December versus May (RDV, 87% vs 40%; corticosteroids, 93% vs 62%; convalescent plasma, 68% vs 26%). There was a shift toward initiating RDV in patients on NSOc or LFO (68.0% [May] vs 83.1% [December]). Median LOS decreased over time. Overall mortality was 13.5% and it was highest for severe patients (invasive mechanical ventilation/extracorporeal membrane oxygenation [IMV/ECMO], 53.7%; high-flow oxygen/noninvasive ventilation [HFO/NIV], 32.2%; LFO, 11.7%; NSOc, 7.3%). The ICU use decreased, whereas mortality decreased for NSOc and LFO. Conclusions Clinical management of COVID-19 is rapidly evolving. This large observational study found that use of evidence-based treatments increased from May to December 2020, whereas improvement in outcomes occurred over this time-period.

Funder

Gilead Sciences

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference25 articles.

1. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control.;Helmy;J Clin Med,2020

2. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.;Flisiak;Pol Arch Intern Med,2021

3. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic.;Asch;JAMA Intern Med,2021

4. Trends in COVID-19 risk-adjusted mortality rates.;Horwitz;J Hosp Med,2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3